研究者詳細 - 國定　俊之

論文 - 國定　俊之

分割表示 556 件中 341 - 360 件目／全件表示 >>

骨・軟部肉腫に対する腫瘍融解ウイルスの放射線増感作用

大森敏規, 山川泰明, 長谷井嬢, 田澤大, 尾崎修平, 杉生和久, 藤原智洋, 国定俊之, 浦田泰生, 藤原俊義, 尾崎敏文

日本整形外科学会雑誌 90 ( 6 ) S1260 - S1260 2016年6月

骨・軟部腫瘍外科における手術支援ナビゲーションシステムを用いた骨・軟部腫瘍手術

国定俊之, 武田健, 藤原智洋, 瀧川朋亨, 荒瀧慎也, 尾崎敏文

日本整形外科学会雑誌 90 ( 6 ) S1296 - S1296 2016年6月

血清中分泌型microRNAをマーカーとした軟部肉腫の鑑別

吉田晶, 藤原智洋, 魚谷弘二, 森田卓也, 武田健, 国定俊之, 根津悠, 川井章, 落谷孝広, 尾崎敏文

日本整形外科学会雑誌 90 ( 6 ) S1275 - S1275 2016年6月

Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy 査読

Nobuhito Araki, Shunji Takahashi, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Mitsuru Takahashi, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Akira Kawai

EUROPEAN JOURNAL OF CANCER 56 122 - 130 2016年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCI LTD

Aim: Our randomised phase II study showed the clinical benefit of trabectedin compared with best supportive care (BSC) in patients with advanced translocation-related sarcomas after the failure of standard chemotherapy. The aim of the present study was to evaluate efficacy and safety of trabectedin in the identical patients crossed over to trabectedin after disease progression in the BSC arm of the randomised study.
Patients and methods: This was a single-arm study of the BSC patients of the randomised study in whom disease progressed. Trabectedin (1.2 mg/m(2)) was administered over 24 h on day 1 of a 21-d treatment cycle. The efficacy and safety of trabectedin after BSC were evaluated and retrospectively compared with the results of the randomised study.
Results: Thirty patients crossed over to trabectedin. Median progression-free survival (PFS) was 7.3 months (95% confidence interval [CI]: 2.9-9.1) after crossover compared with 0.9 months (95% CI: 0.9-1.0) at BSC in the randomised study. PFS in the present study was comparable to that of the trabectedin arm in the randomised study. The number of patients with growth modulation index >= 1.33 was 25 (86%). Individual tumour volume was decreased in 11 patients after crossover. Adverse drug reactions (ADRs) were observed in 27 patients (96.4%). ADRs of grade III-IV were mainly bone marrow suppression and abnormal liver functions.
Conclusion: Trabectedin was revealed to be effective and well tolerated in the identical patients crossed over to trabectedin after disease progression in BSC. The present study is registered with the Japan Pharmaceutical Information Center, number JapicCTI-121853. (C) 2015 The Authors. Published by Elsevier Ltd.

DOI： 10.1016/j.ejca.2015.12.014

Web of Science

PubMed

researchmap

術中ナビゲーションを用いて切除し得た脛骨原発phosphaturic mesenchymal tumorの一例

藤原智洋, 国定俊之, 武田健, 西山悠紀, 稲垣兼一, 尾崎敏文

中部日本整形外科災害外科学会雑誌 59 ( 春季学会 ) 171 - 171 2016年3月

ラジオ波焼灼術(RFA)を行った類骨骨腫の治療成績

国定俊之, 武田健, 藤原智洋, 郷原英夫, 金澤右, 尾崎敏文

日本整形外科学会雑誌 90 ( 3 ) S843 - S843 2016年3月

Circulating microRNAの新規バイオマーカーとしての可能性の検証骨肉腫診療における可能性

藤原智洋, 魚谷弘二, 吉田晶, 森田卓也, 武田健, 国定俊之, 川井章, 根津悠, 落谷孝広, 尾崎敏文

日本整形外科学会雑誌 90 ( 3 ) S611 - S611 2016年3月

胞巣状軟部肉腫の特徴的な画像所見

国定俊之, 武田健, 藤原智洋, 魚谷弘二, 杉生和久, 尾崎敏文

中部日本整形外科災害外科学会雑誌 59 ( 春季学会 ) 89 - 89 2016年3月

骨・軟部肉腫切除後にプレート固定した自家処理骨移植の治療成績

武田健, 国定俊之, 森田卓也, 小松原将, 魚谷弘二, 杉生和久, 藤原智洋, 杉原進介, 尾崎敏文

日本整形外科学会雑誌 90 ( 2 ) S171 - S171 2016年3月

【3Dモデル・3Dプリンターを利用した整形外科手術】整形外科分野への応用 3D実体モデルを利用した骨・軟部腫瘍手術

武田健, 中原龍一, 原田遼三, 国定俊之, 尾崎敏文

関節外科 35 ( 2 ) 198 - 204 2016年2月

Limb salvage surgery for pelvic osteosarcoma 査読

Toshiyuki Kunisada, Ken Takeda, Tomohiro Fujiwara, Shinsuke Sugihara, Toshifumi Ozaki

Osteosarcoma 135 - 147 2016年1月

記述言語：英語掲載種別：論文集(書籍)内論文出版者・発行元：Springer Japan

Patients with pelvic osteosarcoma have a poor outcome
treatment is one of the most challenging problems for the orthopedic oncologist. The reconstructive approach varies according to anatomic location, extent of resection, the patient’s functional demands, and individual surgeon preference. The choice of optimal technique for reconstruction after acetabular tumor resection depends on numerous parameters and includes iliofemoral arthrodesis or pseudoarthrodesis, combined use of hip arthroplasty with massive allograft or recycled autograft, and pelvic and saddle prosthesis. The type of reconstruction modality can influence the rate of infection. Hip transposition resulted in the least incidence of complications after resection of the acetabulum, compared to the use of prosthesis or prosthesis and allograft. The absence of large implants and allografts helps reduce surgical time, facilitates closure, and may decrease the incidence of infection and late revision due to implant failure. These can lead to early postoperative systemic treatment and functional recovery and are critical for patients with a high incidence of local recurrence and distant metastases. We believe that resection arthroplasty should be indicated for the patient with acetabular osteosarcoma.

DOI： 10.1007/978-4-431-55696-1_11

Scopus

researchmap

骨腫瘍切除後の骨欠損に対する配向連通気孔構造を有した新しい人工骨移植の治療成績

武田健, 国定俊之, 藤原智洋, 尾崎敏文

移植 50 ( 6 ) 666 - 666 2015年12月

Prominent thallium-201 uptake of giant cell tumor of bone : comparison with osteosarcoma

R. Inai, S. Takayoshi, T. Tanaka, Y. Tsuboi, S. Norikane, K. Kojima, A. Tada, T. Kunisada, S. Sato, T. Ozaki, S. Kanazawa

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42 S783 - S784 2015年10月

Diagnostic value of Thallium-201 scintigraphy in differentiating malignant bone tumors from benign bone lesions 査読

Ryota Inai, Takayoshi Shinya, Akihiro Tada, Shuhei Sato, Tomohiro Fujiwara, Ken Takeda, Toshiyuki Kunisada, Hiroyuki Yanai, Toshifumi Ozaki, Susumu Kanazawa

ANNALS OF NUCLEAR MEDICINE 29 ( 8 ) 674 - 681 2015年10月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：SPRINGER

This retrospective study aims to evaluate the diagnostic capacity of thallium-201 (201Tl) scintigraphy for differentiating malignant bone tumors from benign bone lesions.
Between January 2006 and December 2012, 279 patients with bone lesions (51 malignant and 228 benign) underwent 201Tl scintigraphy before treatment. To evaluate 201Tl uptake, we investigated tumor-to-background contrast (TBC) as well as TBC washout rate (WR). The differences of TBC on early and delayed images and WR were estimated by the Mann-Whitney U test. Receiver operating characteristic (ROC) analyses were used to determine the cut-off TBC values for differentiating malignant bone tumors from benign bone lesions.
There were statistically significant differences in median TBC between malignant tumors and benign lesions. These differences occurred for early imaging (1.57 vs. 0.09, p < 0.001) as well as for delayed imaging (0.83 vs. 0.07, p < 0.001). However, there was no statistical difference in WR between malignant tumors and benign lesions (44 vs. 43 %, NS). The chosen TBC cut-off value was 0.68 for early imaging and 0.38 for delayed imaging. Using these cut-off values, the prediction of malignancy had a 77 % sensitivity, 74 % specificity, and 75 % accuracy for early imaging and an 80 % sensitivity, 76 % specificity, and 77 % accuracy for delayed imaging.
201Tl scintigraphy may have the ability to distinguish malignant bone tumors from benign bone lesions.

DOI： 10.1007/s12149-015-0990-6

Web of Science

PubMed

researchmap

RPN2は骨肉腫の様々な悪性形質を制御し臨床予後を規定する

藤原智洋, 根津悠, 吉田晶, 魚谷弘二, 国定俊之, 武田健, 森田卓也, 小松原将, 杉生和久, 大森敏規, 川井章, 落谷孝広, 尾崎敏文

日本癌学会総会記事 74回 P - 3207 2015年10月

Ewing肉腫に対する新しい診断法のためのエクソソーム表面マーカーの網羅的解析

魚谷弘二, 藤原智洋, 吉田晶, 森田卓也, 武田健, 国定俊之, 吉岡祐亮, 植田幸嗣, 落谷孝広, 尾崎敏文

日本癌学会総会記事 74回 P - 1356 2015年10月

骨肉腫に対するドキソルビシンとp53発現腫瘍融解アデノウイルス製剤の併用療法

杉生和久, 田澤大, 長谷井嬢, 尾崎修平, 山川泰明, 大森敏規, 小松原将, 魚谷弘二, 藤原智洋, 国定俊之, 浦田泰生, 尾崎敏文, 藤原俊義

日本癌学会総会記事 74回 P - 1382 2015年10月

滑膜肉腫患者における分泌型microRNAの特定と新規バイオマーカーとしての実験的検証

吉田晶, 藤原智洋, 魚谷弘二, 根津悠, 武田健, 国定俊之, 川井章, 落谷孝広, 尾崎敏文

日本癌学会総会記事 74回 P - 3280 2015年10月

骨軟部肉腫細胞に対する腫瘍融解ウイルスの放射線増感作用

大森敏規, 山川泰明, 長谷井嬢, 田澤大, 尾崎修平, 佐々木剛, 杉生和久, 魚谷弘二, 藤原智洋, 国定俊之, 浦田泰生, 尾崎敏文, 藤原俊義

日本癌学会総会記事 74回 E - 1276 2015年10月

Final results of a randomized phase II study comparing trabectedin and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS)

T. Kunisada, S. Takahashi, N. Araki, H. Sugiura, T. Ueda, T. Yonemoto, M. Takahashi, H. Morioka, H. Hiraga, T. Hiruma, A. Matsumine, A. Kawai

EUROPEAN JOURNAL OF CANCER 51 S704 - S704 2015年9月

　前のページ - 次のページ　

<國定 俊之>

論文 - 國定 俊之

<國定　俊之>

論文 - 國定　俊之